← Leaderboards
David Burkhart
Inimmune Corporation
$5,907,864
Attributed
$5,907,864
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.5M · FY2023–25$5M$3.8M$2.5M$1.3M$0
'23
'24
'25
Funding mix
By agency
NIH$5,907,864 · 1
By mechanism
N01$5,907,864 · 1
Top collaborators
No co-investigators on record.
Most similar at Inimmune Corporation
Same institution · by research overlap
- Juhienah Khalaf$3,072,270
- Shannon Miller$1,992,471
- Omer Rasheed$598,808
Others in their field
Other Rising Stars on “Viral Vaccines”
- Angee Greer · Ppd Development Lp$82,531,927
- Jason Dickens · Duke University$12,259,409
- Jeff T Hutchins · Inhalon Biopharma, Inc.$9,192,272
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- Stacey House · Washington University$7,894,662
- Timothy O'Connor · Rockefeller University$7,019,416
Research focus
Viral VaccinesAdjuvantAgonistAntibodiesAntigensBacterial VaccinesChemistryCollaborationsContractorContractsCyclic GmpDrug KineticsExcretory FunctionExhibitsFerretsFormulationGenerationsHeadImmune ResponseImmunogenicityInfluenza A Virus, H1n1 SubtypeInfluenza A Virus, H3n2 SubtypeInfluenza B VirusInfluenza Virus Vaccine
Grant awards (3)
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES$1,648,211
N01 · FY2025 · AI · contact PI
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES$2,515,245
N01 · FY2024 · AI · contact PI
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES$1,744,408
N01 · FY2023 · AI · contact PI